Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

Ludwig Kappos, Ernst‐Wilhelm Radue, Paul O’Connor et al. · New England Journal of Medicine · 2010 · 2.6K citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Gavin Giovannoni et al. · New England Journal of Medicine · 2016 · 2K citations · Full text

Life Sciences, Immunology, Neurology +17

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

Ann Marie Weideman, Marco Aurelio Tapia-Maltos, Kory Johnson et al. · Frontiers in Neurology · 2017 · 306 citations · Full text

Pharmacy, Biostatistics, Pharmacotherapy +16

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

Paul O’Connor, Andrew Goodman, Ludwig Kappos et al. · Neurology · 2011 · 297 citations

Life Sciences, Neurology, Pharmacotherapy +15

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

Per Soelberg Sørensen, Nils Koch‐Henriksen, Thor Petersen et al. · Journal of Neurology · 2014 · 141 citations

Medicine, Clinical Sciences, Pharmacotherapy +12